# A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis

> **NCT03493269** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers
- Psoriasis

## Interventions

- **DRUG:** BAY1834845
- **OTHER:** Matching Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03493269
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-16
- **Primary completion:** 2020-09-16
- **Final completion:** 2021-02-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493269, "A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03493269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*